The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL
- Registration Number
- NCT00347737
- Lead Sponsor
- Leland Graves III, MD
- Brief Summary
The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).
- Detailed Description
Research subjects participation is about 6 months. Subjects will give themselves daily injections of teriparatide after instruction on technique.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide
Read More
Exclusion Criteria
- Patients with diabetes mellitus
- current smokers
- patients with a history of organ transplantation
- Patients currently of previously on glucocorticoid therapy within the past year
- Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater)
- Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis
- History of radiation therapy
- Patients pregnant or nursing
- History of bone metastasis or skeletal malignancies
- History of hypercalcemia
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 teriparatide Teriparatide
- Primary Outcome Measures
Name Time Method The study measures changes in vascular compliance with teriparatide 1 hour, 3 months, and 6 months after initiating teriparatide. Osteoprotegerin and RANKL levels baseline, 3, and 6 months
- Secondary Outcome Measures
Name Time Method CRP levels Baseline and at 6 months of therapy
Trial Locations
- Locations (1)
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States